Lazard Asset Management LLC Has $1.63 Million Stock Position in LivaNova PLC (NASDAQ:LIVN)

Lazard Asset Management LLC boosted its stake in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 145.1% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 35,156 shares of the company's stock after purchasing an additional 20,813 shares during the period. Lazard Asset Management LLC owned 0.06% of LivaNova worth $1,628,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. KBC Group NV boosted its position in LivaNova by 130.5% during the fourth quarter. KBC Group NV now owns 99,928 shares of the company's stock valued at $4,628,000 after purchasing an additional 56,580 shares during the last quarter. PNC Financial Services Group Inc. boosted its position in LivaNova by 29.1% during the fourth quarter. PNC Financial Services Group Inc. now owns 6,311 shares of the company's stock valued at $292,000 after purchasing an additional 1,424 shares during the last quarter. Rhumbline Advisers boosted its position in LivaNova by 0.5% during the fourth quarter. Rhumbline Advisers now owns 177,938 shares of the company's stock valued at $8,240,000 after purchasing an additional 899 shares during the last quarter. Susquehanna Fundamental Investments LLC acquired a new position in LivaNova during the fourth quarter valued at approximately $2,772,000. Finally, Envestnet Asset Management Inc. boosted its position in LivaNova by 15.4% during the fourth quarter. Envestnet Asset Management Inc. now owns 43,932 shares of the company's stock valued at $2,034,000 after purchasing an additional 5,850 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. Robert W. Baird increased their price target on LivaNova from $55.00 to $61.00 and gave the company an "outperform" rating in a research report on Thursday, May 8th. Barclays cut their price objective on LivaNova from $56.00 to $55.00 and set an "equal weight" rating for the company in a research report on Thursday, May 8th. Wolfe Research raised LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 price objective for the company in a research report on Tuesday. Wall Street Zen cut LivaNova from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 8th. Finally, Mizuho cut their price objective on LivaNova from $70.00 to $60.00 and set an "outperform" rating for the company in a research report on Wednesday, February 26th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Buy" and an average target price of $59.29.

LivaNova Stock Performance

Shares of NASDAQ LIVN traded down $1.30 during trading hours on Friday, reaching $41.88. 602,740 shares of the stock were exchanged, compared to its average volume of 651,153. The firm has a market capitalization of $2.28 billion, a price-to-earnings ratio of 99.71 and a beta of 0.84. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. LivaNova PLC has a 52 week low of $32.48 and a 52 week high of $61.94. The stock's fifty day simple moving average is $38.77 and its 200 day simple moving average is $44.60.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.